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Patients unﬁt for neoadjuvant therapy may still
undergo resection of locally advanced esophageal
or esophagogastric junctional cancer with
acceptable oncological results
J. Robert O’Neill, PhD, MRCSEda*, Ewan D. Kennedy, MBChB (Hons)a, Vicki Save, FRCPathb,
Barbara Langdale-Brown, FRCPathb, Lucy Wall, MD, FRCPc, Richard J.E. Skipworth, MD, FRCSEda,
Simon Paterson-Brown, MS, FRCSEda
Introduction: Neoadjuvant chemotherapy (NA) is routinely offered to patients undergoing resection for locally advanced (≥ cT3Nx
or cTxN+ ) esophageal or esophagogastric junctional (EGJ) cancer in the United Kingdom. Patients with comorbidity precluding the
use of NA can be considered for resection yet the effect of omitting NA on survival is unclear.
Methods: Retrospective review of prospectively collected clinical data from patients undergoing attempted curative therapy for
≥ cT3Nx or cTxN+ esophageal or EGJ (Siewert type I-III) cancer between 2001 and 2013.
Results: NA was commenced in 289 patients and primarily comprised 2 cycles of cisplatin and 5-ﬂuorouracil (264 patients, 91%).
Surgery alone was planned for 82 patients with NA omitted due to comorbidity. Patients undergoing surgery alone were matched for
clinical variables and stage with those undergoing NA but were signiﬁcantly older (mean= 8 y, P<0.001). NAwas associated with an
improved median overall survival of 28.7 months, compared with 20.9 months for patients undergoing surgery alone (P= 0.008).
Patients undergoing surgery alone had a 90-day postoperative mortality rate of 10% compared with 3% for those undergoing NA
(P=0.011). In patients discharged postoperatively, the median overall survival beneﬁt of NAwas 2.7months (P=0.048). Those 19%
of patients experiencing a signiﬁcant histologic response to NA demonstrated further improved survival.
Conclusions: NA improves survival in patients undergoing resection for locally advanced esophageal or EGJ cancer; however, the
median beneﬁt is <3 months in patients discharged postoperatively. Patients precluded from NA achieve acceptable oncological
results but experience a higher risk of perioperative mortality.
Keywords: Esophageal cancer, Esophagogastric junctional cancer, Neoadjuvant chemotherapy, Mandard
Introduction
Esophageal cancer is the eighth most common cancer and sixth
leading cause of cancer death worldwide [1]. Radical surgical
resection remains an essential component of curative therapy yet
even with a microscopically complete (R0) resection, many
patients relapse with systemic metastases and < 40% survive
5 years from diagnosis [2].
Neoadjuvant chemotherapy (NA) has been proposed to
improve survival due to tumor downstaging [3–5], and treatment
of systemic micrometastases [6]. A meta-analysis reported an
absolute 2-year survival advantage of 5.1% associated with the
use of NA compared with surgery alone for esophageal cancer [7].
In the United Kingdom, NA is therefore considered the standard
of care for patients undergoing resection for locally advanced
(≥ clinical T3; ≥ cT3 and/or node-positive; cN+ ) esophageal or
esophagogastric junctional (EGJ) cancer [8]. A signiﬁcant survival
beneﬁt has also been identiﬁed after neoadjuvant chemor-
adiotherapy and the optimal preoperative regime is the topic of
ongoing research [9–11].
The neoadjuvant use of cisplatin and 5-ﬂuorouracil (5-FU)
confers a signiﬁcant risk of cardiac, renal, and other toxicities,
which may impair the ability to withstand subsequent major
surgery [12,13], and NA treatment-related mortalities are reported
[14]. The response to NA is variable and evidence is mounting that
the majority of the survival beneﬁt fromNA is derived by a subset
of patients exhibiting a signiﬁcant histologic response [3,15–21].
The remaining patients experience little or no beneﬁt, yet still
the potential harm from NA toxicity and delay to surgical
resection [22,23]. Positron emission tomography (PET) has been
used to assess early tumor response during NA chemotherapy,
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although the accuracy of this technique has yet to be determined
and unfortunately, no test has been approved to predict if patients
with esophageal or EGJ cancer will respond to NA [24–27].
Histopathologic examination of the ﬁnal resected specimen
remains the standard method of determining tumor
regression [15,28]. Several systems using a tiered tumor regression
score have been proposed and although none have gained uni-
versal acceptance, the most widely used method is that of
Mandard et al[28] (Supplemental Table 1, Supplemental Digital
Content 1, http://links.lww.com/IJSO/A0) [29,30].
Contemporary improvements in perioperative care allow
patients with locally advanced esophageal cancer yet comorbid-
ities precluding the use of NA, to undergo esophageal resection
with acceptable in-hospital mortality rates [31]. The oncological
outcome for these patients after surgery alone is not clear, as data
from historical cohorts before the routine use of NA may be
confounded by poorer quality preoperative staging and
perioperative care.
The aim of this single center, retrospective cohort study was to
determine the contemporary outcome after surgery alone for
patients with locally advanced esophageal cancer (≥ cT3Nx or
cTxN+ ) precluded from NA due to comorbidity and compare it
with clinically stage-matched patients undergoing NA and
surgery.
Methods
Deidentiﬁed treatment and outcome data were retrospectively
obtained from a prospectively maintained audit database
including patients undergoing attempted curative therapy for
mid, distal esophageal or EGJ (Siewert type I-III) adenocarci-
noma, or squamous cell carcinoma between January 2001 and
December 2013 at a single tertiary referral center. Additional
patient consent and ethical approval were not required as only
data obtained as part of routine clinical care were used for this
study. As standards of clinical and pathologic staging changed
during the study period, original staging investigations, pathol-
ogy reports and, if necessary, specimens were re-examined and
reported using the criteria of the 7th Edition of the TNM staging
manual [32].
All patients considered ﬁt for surgical resection were staged by
a multidisciplinary team comprising esophagogastric surgeons,
gastroenterologists, oncologists, radiologists, and pathologists
using a combination of endoscopy, chest and abdominal com-
puted tomography (CT), CT-PET, endoscopic ultrasound (EUS),
and laparoscopy. The clinical stage and tumor length were
derived from the EUS, or if no EUS was conducted, from a
combination of CT, CT-PET, and laparoscopy, using the highest
cT and cN stage.
Patients staged as cT1N0 or cT2N0 were not considered for
NA and were excluded from analysis. Those patients staged as
cT3Nx, cT4aNx, or cTxN+ with resectable disease and no
contraindications were offered NA followed by surgery.
Patients with esophageal or Siewert type I or II EGJ tumors
were givenNA comprising 2 cycles of cisplatin (80mg/m2) on day
1 and 5-FU (1 g/m2) on days 1 to 4 every 21 days (2×CF).
Resection then comprised an en bloc esophageal and gastric
dissection with a mediastinal and upper abdominal lymphade-
nectomy (Ivor-Lewis esophagogastrectomy) or, for occasional
bulky type II tumors, a lower mediastinal and upper abdominal
lymphadenectomy was performed with a left thoracoabdominal
esophagogastrectomy. Rarely, for frail patients, a transhiatal
approach was used.
Patients with Siewert type III EGJ tumors were given epirubicin
50mg/m2 on day 1, cisplatin 60mg/m2 on day 1, and capecitabine
1250mg/m2/d continuously (ECX) for 3, 21-day preoperative
cycles. Resection then comprised a left thoracoabdominal esopha-
gogastrectomy, or extended total gastrectomy.
A small proportion of patientswith esophageal and Siewert type I
and II EGJ tumors received 4 cycles of preoperative ECXas part of a
clinical trial. Neoadjuvant radiotherapywas not used. All resections
were tailored to the tumor location and patient comorbidity and
were planned for between 4 and 8 weeks after completion of NA.
NA was considered contraindicated in patients with an esti-
mated glomerular ﬁltration rate <60mL/min, symptomatic
ischemic heart disease or peripheral vascular disease, a history of
myocardial infarction or cerebrovascular accident within the
previous 12 months, previous peripheral vascular disease
requiring surgery or signiﬁcant hearing impairment already
requiring a hearing aid. Additional patients with cardiovascular
comorbidities less signiﬁcant than those above were reviewed in
an oncology clinic and a collaborative decision reached as to
proceeding with NA or going directly to surgery.
A microscopically incomplete (R1) resection was deﬁned as
tumor cells within 1mm of any resection margin, tumor differ-
entiation by the most poorly differentiated area, and pathologic
size as the maximum in any dimension [33]. Histologic response to
NA was retrospectively assessed using the Mandard system [28]
(Supplemental Table 1, Supplemental Digital Content 1, http://
links.lww.com/IJSO/A0) for a random subgroup of patients
undergoing NA and surgery by 2 specialist upper-gastrointestinal
pathologists, blinded to clinical and outcome data, through
review of the diagnostic slides produced at the time of resection.
Postoperative radiotherapy, chemotherapy, or observation
alone were offered by the multidisciplinary team after review of
the resection pathology, consideration of patient comorbidities,
and postoperative recovery. Recurrence data were obtained from
follow-up consultations with date of recurrence deﬁned as date of
restaging investigation conﬁrming either local (mediastinal or
anastomotic) or distant recurrence. Survival was deﬁned as date
of diagnostic biopsy to death or last follow-up with primary or
tertiary care, censoring on December 31, 2014.
All statistical analysis was performed using “IBM SPSS
Statistics” software (Version 21.0.0, SPSS Inc. Chicago, IL).
Categorical variables are illustrated in tables and were compared
using the χ2 test. Continuous variables were summarized by
medians or means if appropriate and 95% conﬁdence intervals
included in parenthesis unless otherwise stated.
Univariable survival analysis was performed using the Kaplan-
Meier method with a log-rank test of signiﬁcance for categorical
covariates and Cox regression for continuous covariates [2].
Statistical signiﬁcance was deﬁned as a P< 0.05. Covariates sig-
niﬁcantly associated with survival on univariable analysis were
assessed in a Cox proportional hazards model [2].
Results
Of the 497 identiﬁed patients, 126 were excluded for the fol-
lowing reasons; palliative chemotherapy and salvage surgery
(n=3), not considered for NA due to early (cT1N0 or cT2N0)
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Table 1
Cohort clinical characteristics and survival analysis.
Group Clinical Characteristics Association With Overall Survival (Log Rank)
Variables NA and Surgery (n= 289) Surgery Only (n= 82) Difference Between Groups (P) Total Cohort (n= 371) Univariable (P)
Sex [n (%)]
Male 227 (79) 65 (79) 0.888 292 (79) 0.131
Female 62 (21) 17 (21) 79 (21)
Age
Mean (SD) 62.4 (± 8.5) 70.6 (± 8.1) < 0.001 64.2 (± 9.0) 0.331
Tumor location [n (%)]
Eso Mid 1/3 30 (10) 9 (11) 0.188 39 (11) 0.299
Eso Low 1/3 117 (41) 22 (27) 139 (37)
EGJ type I 82 (28) 26 (32) 108 (29)
EGJ type II 40 (14) 16 (20) 56 (15)
EGJ type III 20 (7) 9 (11) 29 (8)
Tumor length (EUS)
Mean (SD) (cm) 5.2 (± 2.1) 4.8 (± 2.1) 0.158 5.1 (± 2.1) P= 0.002; HR= 1.14 (1.05–1.23)
Histology [n (%)]
ACC 233 (81) 71 (86) 0.287 304 (82) 0.175
SCC 56 (19) 11 (14) 67 (18)
Clinical T stage [n (%)]
cT1b 1 (0) 0 0.091 1 (0) 0.070
cT2 23 (8) 13 (16) 36 (10)
cT3 265 (92) 69 (84) 334 (90)
Clinical N stage [n (%)]
cN0 35 (12) 16 (20) 0.102
cN+ 254 (88) 66 (80)
Resected [n (%)]
Yes 274 (95) 80 (98) 0.293 354 (95) < 0.001
No 15 (5) 2 (2) 17 (5)
Resection type [n (%)]
ILE 259 (90) 59 (72) < 0.001 318 (86) 0.835
LTA 9 (3) 11 (13) 20 (5)
ETG 5 (2) 7 (9) 12 (3)
MIE 1 (0) 1 (1) 2 (1)
Transhiatal 0 2 (2) 2 (1)
Bold values are to highlight statistically signiﬁcant values (P< 0.05).
ACC indicates adenocarcinoma; EGJ, esophagogastric junctional; Eso, esophageal; ETG, extended total gastrectomy; EUS, endoscopic ultrasound; HR, hazard ratio; ILE, Ivor-Lewis esophagogastrectomy; LTA, left thoracoabdominal esophagogastrectomy; MIE, minimally invasive
esophagectomy; NA, neoadjuvant chemotherapy; SCC, squamous cell carcinoma.
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Table 2
Cohort pathologic characteristics and survival analysis.
Group Pathologic Characteristics Association With Overall Survival (Log Rank)
Variables NA and Surgery (n= 274) Surgery Only (n= 80) Difference Between Groups (P) Total Cohort (n= 354) Univariable (P)
Tumor size (path)
Mean (SD) (cm) 4.5 (± 2.2) 4.8 (± 2.3) 0.244 4.6 (± 2.2) P< 0.001; HR= 1.2 (1.13–1.26)
Differentiation [n (%)]
Well 8 (3) 2 (3) 0.842 10 (3) < 0.001
Moderate 90 (33) 24 (30) 114 (32)
Poor 174 (64) 54 (67) 228 (64)
No tumor 2 (1) 2 (1)
pT stage [n (%)]
pT0 2 (1) 0 0.889 2 (1) < 0.001
pT1a 2 (1) 0 2 (1)
pT1b 20 (7) 4 (5) 24 (7)
pT2 32 (12) 10 (13) 42 (12)
pT3 201 (73) 59 (74) 260 (73)
pT4a 15 (5) 6 (8) 21 (6)
pT4b 2 (1) 1 (1) 3 (1)
pN stage [n (%)]
pN0 73 (27) 22 (28) 0.143 95 (27) < 0.001
pN1 86 (31) 17 (21) 103 (29)
pN2 59 (22) 16 (20) 75 (21)
pN3 56 (20) 25 (31) 81 (23)
Total nodes resected
Mean (SD) 23 (± 8) 23 (± 9) 0.996 23.3 (± 8) 0.543
Resection status [n (%)]
R0 128 (47) 29 (36) 0.189 157 (44) < 0.001
R1 143 (52) 49 (61) 192 (54)
R2 3 (1) 2 (3) 5 (1)
pT vs. cT [n (%)]
Lower 51 (19) 10 (12) 0.035
Same 196 (72) 54 (68)
Higher 27 (10) 16 (20)
pN vs. cN [n (%)]
Lower 62 (23) 17 (21) 0.302
Same 190 (69) 52 (65)
Higher 22 (8) 11 (14)
Mandard stage [n (%)]
TRG I 2 (1) 2 (1) 0.077
TRG II 3 (1) 3 (1)
TRG III 16 (6) 16 (5)
TRG IV 48 (18) 48 (14)
TRG V 42 (15) 42 (12)
Unknown 163 (60) 80 243 (69)
Mandard stage group [n (%)]
TRG I-III 21 (19) 21 (19) 0.023
TRG IV-V 90 (81) 90 (81)
Bold values are to highlight statistically signiﬁcant values (P< 0.05).
NA indicates neoadjuvant chemotherapy; TRG, Tumor Regression Grade.
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stage (n=47), and clinical staging investigations or pathologic
specimens not available for review (n= 76). The estimated med-
ian survival of the remaining 371 patients was 28.1 months with
an estimated 5-year survival rate of 29% and a median follow-up
for the 148 survivors of 30 months. The cohort clinical char-
acteristics are summarized in Table 1.
NA was commenced in 289 patients and 274 proceeded to
resection (95%) compared with 98% of the 82 patients planned
for surgery alone (P=0.293). NA consisted of 2×CF in 264
patients (91%) or 3 cycles (20 patients; 7%) or 4 cycles (5
patients; 2%) of ECX.
Patients going straight to surgerywere well matchedwith those
undergoing NA for measured clinical variables and stage but
were signiﬁcantly older (mean difference of 8 y, P<0.001). The
type of resection, a reﬂection of tumor position, also differed
signiﬁcantly between groups (P<0.001) but neither age nor
operative approach were associated with overall survival (Table
1). The rate of microscopic (R1) or macroscopic (R2) involve-
ment of resectionmargins also did not differ signiﬁcantly between
groups (P=0.189,Table 2) and amean of 23 nodes were resected
in both groups (Table 2).
On intention to treat, NA was associated with a signiﬁcantly
longer median overall survival of 28.7 months (range, 24.3–33.0
mo), compared with 20.9 months (range, 7.2–34.6 mo) for
patients undergoing surgery alone (P=0.008, Fig. 1A). In con-
trast, disease-speciﬁc survival did not differ signiﬁcantly between
groups [NA—median survival of 33.4 mo (range, 22.2–44.5 mo),
surgery alone—median survival of 29.4 mo (range, 15.7–43.1
mo); P=0.550; Fig. 1B].
The overall 90-day postoperative mortality rate was 4.8% (17/
354 patients). Patients going straight to surgery had a sig-
niﬁcantly higher postoperative mortality rate of 10% (8/80
patients) compared with 3% (9/274 patients) for those under-
going NA and surgery (χ2, P= 0.011). If those patients dying
within 90 postoperative days were excluded, NA was still asso-
ciated with signiﬁcantly longer overall survival (median, 31.3 mo;
range, 26.3–36.3 mo) over surgery alone (median, 28.6 mo;
range, 16.9–40.2 mo; P=0.048; Fig. 2). As all deaths within
90 days were due to postoperative complications rather than
disease recurrences, disease-speciﬁc survival was unchanged.
The use of NAwas independently predictive of overall survival
(hazard ratio, 0.655; range, 0.469–0.914; P=0.013) along with
pathologic tumor size, pN stage, and resection margin status
(Supplemental Table 2, Supplemental Digital Content 2, http://
links.lww.com/IJSO/A1). NA has been proposed to downstage
esophageal tumors. When pT stage was compared with cT stage,
signiﬁcantly fewer patients were upstaged and more were
downstaged after NA compared with surgery alone although the
differences were small (Table 2; P= 0.035). There was also a
trend toward smaller tumors in the NA group (Table 2) but this
difference was not statistically signiﬁcant. No difference was
observed between groups when cN and pN stages were compared
(Table 2; P=0.302).
The histologic response to NA was assessed in a randomly
selected subset (40%) of the 274 patients undergoing NA and
resection. A signiﬁcant histologic response (TRG I-III) was
observed in 21 patients (19%) and was associated with a sig-
niﬁcantly improved overall survival (median, 37.2 mo; range,
26.3–48.2 mo) compared with patients exhibiting no signiﬁcant
histologic response (TRG IV-V), [median, 32.7 mo (range,
21.3–44.1 mo); hazard ratio for mortality= 0.39 (range,
0.168–0.907); P= 0.023; Fig. 3].
Discussion
Increasing numbers of patients considered ﬁt enough for surgical
resection of ≥ cT3Nx or cTxN+ esophageal or EGJ cancer
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Figure 1. The effect of neoadjuvant chemotherapy on survival. A, Kaplan Meier
plot demonstrating overall survival on intention to treat. Estimated 2-year sur-
vival rate; neoadjuvant (NA) 57%, none (surgery alone) 48%. Estimated 5-year
survival rate; NA 31%, none 19%. B, Kaplan Meier plot demonstrating disease-
speciﬁc survival on intention to treat. Estimated 2-year survival rate; NA 59%,
none 55%. Estimated 5-year survival rate; NA 39%, none 37%.
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present with comorbidities precluding the use of NA. This ret-
rospective study examined the effect of omitting NA on the sur-
vival of these patients.
NA was associated with a median overall survival beneﬁt of
7.8 months (Fig. 1). The beneﬁt of NAwas reduced to 2.7months
when deaths within 90 postoperative days were excluded (Fig. 2).
This is likely due to the higher in-hospital mortality rate of 10%
in patients undergoing surgery alone compared with 3% in
patients undergoing NA before surgery. A similar 90-day, post-
operative mortality rate of 11.3% was reported in a study of 212
patients with cT3 or cT4 disease going straight to surgery [34].
This likely reﬂects the greater comorbidity of the group precluded
from NA.
No signiﬁcant difference in disease-speciﬁc survival could be
determined although a trend in favor of NA was identiﬁed.
Recurrence data were only available for 89% of the cohort,
which reduces the sensitivity to detect a difference. Routine CT
scanning was not used during follow-up with investigations
instigated on clinical suspicion. Symptomatic recurrences were
correspondingly more likely to be identiﬁed; however, it is unli-
kely this introduces a bias in favor of the surgery-alone group. If
routine imaging is used during follow-up after esophageal cancer
surgery the recorded time to recurrence is still a reﬂection of the
time to diagnostic investigation rather than a precise measure of
disease progression.
The ﬁnding of fewer patients upstaged and more downstaged
in the NA group may be taken as evidence of tumor downstaging
(Table 2). However, 21% of patients undergoing surgery alone
were “downstaged” from cN+ to pN0 echoing published ﬁnd-
ings from a similar cohort of 82 patients of whom 16% under-
going surgery alone with cN+ disease were classiﬁed as pN0 [18].
A third of patients going straight to surgery in our study were also
incorrectly T-staged. This highlights the limited accuracy of
current clinical staging methods and caution should be advised
before conclusions of downstaging are drawn from comparison
of clinical and pathologic stages [35].
The NA group predominantly consisted of patients treated
with 2×CF and 19% of a sample of those exhibited a signiﬁcant
histologic response (TRG I-III) with a corresponding longer
median overall survival. Although only a sample of those
undergoing NA were assessed, our ﬁndings are likely to be
representative as a similar signiﬁcant response rate of 15% was
reported in 451 patients with esophageal and EGJ cancer
undergoing NA with 2×CF and resection as part of the OE05
trial [36]. The Radiation Therapy Oncology Group trial 8911
compared surgery alone with preoperative cisplatin and 5-FU and
a long-term follow-up study identiﬁed no difference in survival. A
signiﬁcant response to chemotherapy was, however, noted in
19% of patients and although this was a radiologic rather than
histologic assessment, the responders exhibited similarly sig-
niﬁcantly improved survival [23].
Several further studies have reported a survival beneﬁt in
patients experiencing a signiﬁcant histologic response toNA.One
group reported signiﬁcant response rates (TRG I-III) of 41% in
patients receiving predominantly 3 cycles of ECX and an
improved survival in those patients experiencing the best
response (TRGI-II) compared with the remainder [18]. A similar
signiﬁcant response rate after 4 cycles of ECX was noted in the
OE05 trial [36].
This study does have limitations. Although a consecutive series
of patients was identiﬁed from 1 institution, 76 of the total 450
eligible patients (17%) were excluded due to missing clinical
staging investigations, pathology reports, or specimens and this
may confound the conclusions through selection bias. Patients
undergoing surgery alone were all eligible for chemotherapy on
the basis of clinical staging but went straight to surgery due to
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comorbidity precluding the use of NA. A detailed proﬁle of
comorbidity was not prospectively collected but cardiovascular
and/or renal disease were the reasons for excluding NA in the
majority of cases.
We propose that patient comorbidity is responsible for the
higher 90-day postoperative mortality rate in the surgery-alone
group. An alternative explanation would be that chemotherapy is
protective in the postoperative period. The 47 excluded patients
with cT1N0 or cT2N0 disease had a 90-day postoperative mor-
tality rate of 4% (2 patients), however, similar to those under-
going chemotherapy. Similarly, the published trials of NA in
esophageal cancer do not support a protective effect on 90-day
postoperative mortality [7].
In conclusion, this study reports acceptable oncological out-
comes for patients precluded from NA yet undergoing attempted
curative surgery for locally advanced esophageal cancer.
Therefore, despite higher 90-day postoperative mortality rates,
patients with cardiovascular and renal disease should not be
denied major esophagogastic cancer resection.
Neoadjuvant therapy was associated with improved survival,
although in patients surviving to hospital discharge, this beneﬁt
was < 3 months. The survival beneﬁt was greater in the 19% of
patients exhibiting a signiﬁcant histologic response to therapy.
Pretreatment tests to identify those patients likely to respond are
urgently required.
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